NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM โ In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast Read More
Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
IRVINE, CA and AMSTERDAM โ In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular Read More
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 โ Innovative research by Rene Bernards, Ph.D., the co-founder of Agendia, Inc., has identified a gene signature that has potential to identify which patients will benefit from tamoxifen Read More